The clinical utility of [68Ga]-labelled fibroblast activation protein inhibitor (FAPI) positron emission tomography and computed tomography (PET/CT) in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemotherapy.

Metro South Health0 个研究点目标入组 20 人开始时间: 2023年5月19日最近更新: 2024年6月24日

适应症

试验速览

暂无简介。

•Age greater than or equal to 18years
•- Able to give informed consent
•- Histological specimen from the primary pancreatic lesion confirming the diagnosis of PDAC.
•- Patients need to have either a resectable or borderline resectable pancreatic lesion after imaging review at the HPB multidisciplinary (MDT) meeting
•- No metastatic disease
•- Eastern Cooperative Oncology Group performance status of less than or equal to 1
•- No contraindications to neoadjuvant chemotherapy.

•- Patients not medically fit for peri-operative chemotherapy with FOLFIRINOX or surgery
•- Patients with known or suspected metastatic disease
•- Pregnant or breastfeeding patients (if a female patient is pre-menopausal, she will require a negative urine pregnancy test prior to enrolment)
•- Patients with allergies to or contraindications to [68 Ga] FAPI or [18F] FDG tracer
•- Patients who have had surgery or chemotherapy prior to 1st PET/CT imaging.

发起方

Metro South Health